Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 6Withdrawn 2Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × ganitumab × Clear all
NCT01479179 2016-10-26

Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

NCT01473303 2016-06-28

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer

Alliance for Clinical Trials in Oncology

Phase 1/2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡